Información del artículo
Resumen
El aumento en la prevalencia de la demencia en nuestro entorno supone un reto diagnóstico para el especialista en medicina nuclear. El objetivo de este trabajo es revisar las modificaciones en el procedimiento, y describir la utilidad del uso de la PET cerebral con 18F-FDG en diferentes indicaciones clínicas, tanto clásicas como emergentes. Desde el grupo de trabajo de Neuroimagen de la SEMNIM se ha considerado procedente actualizar los procedimientos disponibles en castellano que permita optimizar la calidad de esta técnica y la interpretación de sus hallazgos, tanto para el especialista en medicina nuclear y el resto de los profesionales involucrados en el diagnóstico y tratamiento de las enfermedades neurodegenerativas.
Palabras clave:
PET
18F-FDG
Demencia
Enfermedad de Alzheimer
Degeneración frontotemporal
Sinucleinopatías
Enfermedades priónicas
Neurología
Procedimiento
Abstract
The increase in the prevalence of dementia in our clinical setting poses a diagnostic challenge for the Nuclear Medicine specialist. The aim of this study is to review the modifications in the procedure and to describe the usefulness of the use of brain PET with 18F-FDG in different clinical indications, both classic and emerging ones. The SEMNIM Neuroimaging working group has considered appropriate to update the procedures available in Spanish, in order to optimize the quality of this technique and the interpretation of its findings, both for the specialist in Nuclear Medicine and the rest of the professionals involved in the diagnosis and treatment of neurodegenerative diseases.
Keywords:
PET
18F-FDG
Dementia
Alzheimer's disease
Frontotemporal degeneration
Synucleinopathies
Prionic diseases
Neurology
Procedure
Artículo
Opciones para acceder a los textos completos de la publicación Revista Española de Medicina Nuclear e Imagen Molecular
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
J.F. Jiménez Bonilla, J.M. Carril Carril.
La neuroimagen molecular en las demencias degenerativas.
Rev Esp Med Nucl Imagen Mol, 32 (2013), pp. 301-309
[2]
J. Arbizu, G. García-Ribas, I. Carrió, P. Garrastachu, P. Martínez-Lage, J.L. Molinuevo.
Recomendaciones para la utilización de biomarcadores de imagen PET en el proceso diagnóstico de las enfermedades neurodegenerativas que cursan con demencia: documento de consenso SEMNIM y SEN.
Rev Esp Med Nucl Imagen Mol, 34 (2015), pp. 303-313
[3]
F. Nobili, J. Arbizu, F. Bouwman, A. Drzezga, F. Agosta, P. Nestor, et al.
European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus.
Eur J Neurol, 25 (2018), pp. 1201-1217
[4]
J. Arbizu, S. Morbelli, S. Minoshima, H. Barthel, P. Kuo, D. van Weehaeghe, et al.
SNMMI Procedure Standard/EANM Practice Guideline for Brain [18 F]FDG PET Imaging, Version 2.0.
J Nucl Med, (2024),
[5]
K. Herholz.
Guidance for reading FDG PET scans in dementia patients.
Q J Nucl Med Mol Imaging, 58 (2014), pp. 332-343
[6]
F. Nobili, C. Festari, D. Altomare, F. Agosta, S. Orini, K. van Laere, et al.
Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders.
Eur J Nucl Med Mol Imaging, 45 (2018), pp. 1557-1566
[7]
M.L. Gorno-Tempini, A.E. Hillis, S. Weintraub, A. Kertesz, M. Mendez, S.F. Cappa, et al.
Classification of primary progressive aphasia and its variants.
Neurology, 76 (2011), pp. 1006-1014
[8]
A. Niñerola-Baizán, P. Aguiar, M.N. Cabrera-Martín, C. Vigil, A. Gómez-Grande, C. Lorenzo, et al.
Relevancia de la cuantificación en los estudios PET cerebrales con 18F-FDG.
Rev Esp Med Nucl Imagen Mol, 39 (2020), pp. 184-192
[9]
K.A. Jellinger.
Neuropathological assessment of the Alzheimer spectrum.
J Neural Transm, 127 (2020), pp. 1229-1256
[10]
G. Chételat.
Aβ-independent processes-rethinking preclinical AD.
Nat Rev Neurol, 9 (2013), pp. 123-124
[11]
E. Salmon, F. Collette, C. Bastin.
Cerebral glucose metabolism in Alzheimer's disease.
Cortex, 179 (2024), pp. 50-61
[12]
S.J. Crutch, J.M. Schott, G.D. Rabinovici, M. Murray, J.S. Snowden, W.M. van der Flier, et al.
Consensus classification of posterior cortical atrophy.
Alzheimers Dement, 13 (2017), pp. 870-884
[13]
J.L. Whitwell, J. Graff-Radford, T.D. Singh, D.A. Drubach, M.L. Senjem, A.J. Spychalla, et al.
18F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies.
J Nucl Med, 58 (2017), pp. 632-638
[14]
M.L. Gorno-Tempini, A.E. Hillis, S. Weintraub, A. Kertesz, M. Mendez, S.F. Cappa, et al.
Classification of primary progressive aphasia and its variants.
Neurology, 76 (2011), pp. 1006-1014
[15]
J.A. Matías-Guiu, M.N. Cabrera-Martín, R. García-Ramos, T. Moreno-Ramos, M. Valles-Salgado, J.L. Carreras, et al.
Evaluation of the New Consensus Criteria for the Diagnosis of Primary Progressive Aphasia Using Fluorodeoxyglucose Positron Emission Tomography.
Dement Geriatr Cogn Disord, 38 (2014), pp. 147-152
[16]
J.A. Matías-Guiu, M.N. Cabrera-Martín, T. Moreno-Ramos, R. García-Ramos, J. Porta-Etessam, J.L. Carreras, et al.
Clinical course of primary progressive aphasia: Clinical and FDG-PET patterns.
J Neurol, 262 (2015), pp. 570-577
[17]
J.L. Whitwell.
FTD spectrum: Neuroimaging across the FTD spectrum.
Prog Mol Biol Transl Sci, 165 (2019), pp. 187-223
[18]
K. Rascovsky, J.R. Hodges, D. Knopman, M.F. Mendez, J.H. Kramer, J. Neuhaus, et al.
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.
Brain, 134 (2011), pp. 2456-2477
[19]
B.T. Peet, S. Spina, N. Mundada, R. la Joie.
Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology.
Neurotherapeutics, 18 (2021), pp. 728-752
[20]
H. Botha, K.A. Josephs.
Primary Progressive Aphasias and Apraxia of Speech.
Continuum (Minneapolis, Minn), 25 (2019), pp. 101-127
[21]
J.A. Matías-Guiu, M.N. Cabrera-Martín, M.J. Pérez-Castejón, T. Moreno-Ramos, C. Rodríguez-Rey, R. García-Ramos, et al.
Visual and statistical analysis of 18F-FDG PET in primary progressive aphasia.
Eur J Nucl Med Mol Imaging, 42 (2015), pp. 916-927
[22]
G.U. Höglinger, G. Respondek, M. Stamelou, C. Kurz, K.A. Josephs, A.E. Lang, et al.
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.
Mov Disord, 32 (2017), pp. 853-864
[23]
P. Alster, N.K. Madetko, D.M. Koziorowski, L. Królicki, S. Budrewicz, A. Friedman.
Accumulation of Tau Protein, Metabolism and Perfusion-Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS).
Front Neurol, 14 (2019), pp. 10
[24]
J. Ge, J. Wu, S. Peng, P. Wu, J. Wang, H. Zhang, et al.
Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: Multivariate and univariate analyses in American and Chinese patient cohorts.
Hum Brain Mapp, 39 (2018), pp. 2842-2858
[25]
A.B. Deutschländer, O.A. Ross, D.W. Dickson, Z.K. Wszolek.
Atypical parkinsonian syndromes: A general neurologist's perspective.
Eur J Neurol, 25 (2018), pp. 41-58
[26]
F. di Stasio, A. Suppa, L. Marsili, N. Upadhyay, F. Asci, M. Bologna, et al.
Corticobasal syndrome: Neuroimaging and neurophysiological advances.
Eur J Neurol, 26 (2019), pp. 701
[27]
J.A. Matías-Guiu, V. Pytel, M.N. Cabrera-Martín, L. Galán, M. Valles-Salgado, A. Guerrero, et al.
Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis.
Eur J Nucl Med Mol Imaging, 43 (2016), pp. 2050-2060
[28]
A. Cistaro, M. Pagani, A. Montuschi, A. Calvo, C. Moglia, A. Canosa, et al.
The metabolic signature of C9orf72-related ALS: FDG PET comparison with nonmutated patients.
Eur J Nucl Med Mol Imaging, 41 (2014), pp. 844-852
[29]
V. Rajagopalan, E.P. Pioro.
Hypometabolic and hypermetabolic brain regions in patients with ALS-FTD show distinct patterns of grey and white matter degeneration: A pilot multimodal neuroimaging study.
Eur J Radiol, 158 (2023), pp. 110616
[30]
M.J. Martí, E. Tolosa, J. Campdelacreu.
Clinical overview of the synucleinopathies.
Mov Disord, 18 (2003), pp. 21-27
[31]
Y. Tang, J. Ge, F. Liu, P. Wu, S. Guo, Z. Liu, et al.
Cerebral Metabolic Differences Associated with Cognitive Impairment in Parkinson's Disease.
PLoS One, 11 (2016),
[32]
F. Albrecht, T. Ballarini, J. Neumann, M.L. Schroeter.
FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson's disease: A whole-brain multimodal imaging meta-analysis.
Neuroimage Clin, 21 (2019), pp. 101594
[33]
L. Wu, F. Liu, J. Ge, J. Zhao, Y. Tang, W. Yu, et al.
Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in 18F-FDG PET imaging.
Hum Brain Mapp, 39 (2018), pp. 4652-4662
[34]
J. Arbizu, M.R. Luquin, J. Abella, R. de la Fuente-Fernández, R. Fernandez-Torrón, D. García-Solís, et al.
Functional neuroimaging in the diagnosis of patients with Parkinsonism: Update and recommendations for clinical use [Article in Spanish].
Rev Esp Med Nucl Imagen Mol, 33 (2014), pp. 215-226
[35]
D.A. López-Mora, V. Camacho, J. Pérez-Pérez, S. Martínez-Horta, A. Fernández, F. Sampedro, et al.
Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
Eur J Nucl Med Mol Imaging, 43 (2016), pp. 2183-2189
[36]
P. Fazio, M. Paucar, P. Svenningsson, A. Varrone.
Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.
Curr Neurol Neurosci Rep, 18 (2018), pp. 85
[37]
E. Prieto, I. Domínguez-Prado, M. Riverol, S. Ortega-Cubero, M.J. Ribelles, M.R. Luquin, et al.
Metabolic patterns in prion diseases: An FDG PET voxel-based analysis.
Eur J Nucl Med Mol Imaging, 42 (2015), pp. 1522-1529
[38]
J.A. Matías-Guiu, C. Guerrero-Márquez, M.N. Cabrera-Martín, U. Gómez-Pinedo, M. Romeral, D. Mayo, et al.
Amyloid- and FDG-PET in sporadic Creutzfeldt-Jakob disease: Correlation with pathological prion protein in neuropathology.
Prion, 11 (2017), pp. 205-213
[39]
D. Perani, P. Cortelli, G. Lucignani, P. Montagna, P. Tinuper, R. Gallassi, et al.
[18F] FDG PET in fatal familial insomnia.
Neurology, 43 (1993),
[40]
C. Achury, V. Camacho, A. Fernández, B. Gómez-Ansón, R. Jaller, I. Carrió.
Hallazgos en el síndrome de Gerstmann-Sträussler-Scheinker en un estudio de PET-TC con 18F-FDG.
Rev Esp Med Nucl Imagen Mol, 31 (2012), pp. 352-353
[41]
V. Kepe, B. Ghetti, M.R. Farlow, M. Bresjanac, K. Miller, S. Huang, et al.
PET of Brain Prion Protein Amyloid in Gerstmann–Sträussler–Scheinker Disease.
Brain Pathol, 20 (2010), pp. 419-430
